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Abstract
The co-occurrence of the three disease entities, inflammatory bowel disease (IBD),
colorectal cancer (CRC), type 2diabetes mellitus (T2DM) along with inflammation and
dismicrobism has been frequently reported. Some authors have even suggested that
dysbiosis could be the link through a molecular crosstalk of multiple inflammatory loops
including TGFβ, NFKB, TNFα and ROS among others.
This review focuses on the inflammatory process along with the role of microbiota in the
pathophysiology of the three diseases.
The etiology of IBD is multifactorial, and like CRC and T2DM, it is associated with a
widespread and sustained GI inflammation and dismicrobism, whereby an array of pro-
inflammatory mediators and other related biomolecules are up-regulated, both locally and
systematically. Such a persistent or an inadequately resolved chronic inflammation may be a
causative agent, in the presence other factors, leading to several pathologies such as IBD,
CRC and T2DM.
TGFβ plays a crucial role in pancreatic β cell malfunctioning as glucotoxicity stimulates its
signaling cascade through smad 3, IL-6 and epithelial to mesenchymal transition. Such a
cascade could lead to macrophages and other cells recruitment, inflammation, then IBD and
CRC.
NFkB is also another key regulator in the crosstalk among the pathways leading to the three
disease entities. It plays a major role in linking inflammation to cancer development through
its ability to up regulate several inflammatory and tumor promoting cytokines like: IL-6, IL-1 α
and TNF α, as well as genes like BCL2 and BCLXL. It activates JAK/STAT signaling
network via STAT3 transcription factors and promotes epithelial to mesenchymal transition.
It also increases the risk for T2DM in obese people. In brief, NFKB is a matchmaker
between inflammation, IBD, cancer and diabetes.
In addition, TNFα plays a pivotal role in systemic inflammation. It is increased in the mucosa
of IBD patients and has a central role in its pathogenesis. It also activates other signaling
pathways like NFKB and MAPK leading to CRC. It is also overexpressed in the adipose
tissues of obese patients thus linking it to T2DM, chronic inflammation and consequently
CRC.
On the other hand, increasing evidence suggests that dysbiosis plays a role in initiating,
maintaining and determining the severity of IBD. Actually, among its functions, it modulates
genotoxic metabolites which are able to induce CRC, a fact proven to be sustained by stool
transfer from patients with CRC. Probiotics, however, may actively prevent CRC as well as
IBD and results in a significant decrease in fasting glycemia in T2DM patients.
In conclusion, IBD, CRC and T2DM are commonly occurring interrelated clinical problems.
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They share a common basis influenced by an inflammatory process, an imbalance in
intestinal microbiota, and a crosstalk between various signaling pathways. Would probiotics
interrupt the crosstalk or orient it in the physiological direction?
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1. Introduction
The medical literature is depleting in publications reporting the co-occurrence of the three
disease entities: inflammatory bowel disease (IBD), colorectal cancer (CRC) and type 2
diabetes mellitus (T2DM), along with inflammation and dismicrobism [8], [17], [21],
[41] and [51]. Actually, the body microbiota represents a complex ecosystem with enormous
microbial diversity. Trillions of bacterial cells colonize the GI surface within the human body
and can reach 10 times the number of the cells forming the whole organism. In addition; the
genes of these microorganisms are 150 times higher in number than those in the human
body. Most of the commensal bacteria are symbiotic; however, they could cause pathology
after their translocation to the mucosa or under specific conditions. The largest number of
bacterial cells is found in the large intestine (1011 per gram of intestinal content), the main
geography of IBD and CRC [19] and [41].
In general, intestinal dysbiosis is associated with an undesirable qualitative and quantitative
alteration in the balance between beneficial and harmful bacteria in the gut [17]. It is also well
documented that changes in the homeostasis of the intestinal microbiota have far-reaching
effects on local and systemic immunity and contribute to the pathogenesis of gastrointestinal
diseases like inflammatory bowel disease, irritable bowel syndrome and colorectal cancer,
as well as extra intestinal systemic diseases like obesity, diabetes and atherosclerosis
among others [57]. Some authors have even suggested that dysbiosis could be the link
between chronic inflammation, IBD, CRC and T2DM trough a crosstalk between several
molecular pathways, in particular, TGFβ, NFKB, TNFα and ROS among others [20]. The
mechanisms forming the basis of such a phenomenon were referred to a series of complex
interactions between the intestinal epithelium, microbiota, genetic factors, and the host
immune system, which modulate the intestinal equilibrium.
Normally, the intestinal epithelium has a critical function as a protective barrier against
luminal antigens. It is covered by a single layer of intestinal epithelial cells (IECs)
distinguished by a fast renewal rate. They are circumferentially tied by intracellular tight
junctions and coated by a thick adherent mucus gel, thus forming a dynamic physical
interface between the host and its environment [35] and [62]. Despite its robust and multi-
faced nature, this barrier can be breached, hence disrupting the intestinal homeostasis, and
thus promoting a state of chronic inflammation in all these three disease entities: IBD, T2DM
and CRC [29].
Normally, inflammation is basically a beneficial activity that rejuvenates injured tissue and
removes the foreign agents disturbing homeostasis, thus leading to recovery of the
equilibrium state. This task is achieved through a complex inflammatory response which
may involve a balance between a huge panel of bioactive molecules, pro and anti-
inflammatory (IL-6, NFKB, TNFα and TGFβ, among others …), provided from resident or
infiltrating inflammatory cells. However, a persistent or an inadequately resolved chronic
inflammation, due to the tilting of the balance in favor of pro-inflammatory agents, may
increase the risk of several pathologies such as IBD, CRC and T2DM. How inflammation
lies on the causative pathway mechanistically linking these three chronic clinical problems
remains unclear [43] and [13].
In this review, the focus is on the inflammation process as constituting the basis in the
development of CRC, IBD and T2DM. Several molecular signaling pathways involved in
such inflammation like TGFβ, JAK/STAT, TNFα, NFkB and ROS production mechanisms
will be discussed, along with the role of microbiota in the physiopathology of these three
diseases. Collectively, the molecular crosstalk between all of these pathways could
probably define the nature of the link or links between all three disease entities.
2. Inflammatory bowel disease
IBD is an idiopathic, chronic, inflammatory disease that affects the colon and other parts of
the gastrointestinal tract. It may also have extra-intestinal manifestations [20]. The exact
etiology of IBD is unrevealed yet, but it is generally known to be multifactorial, with the
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possible leading trigger as a disbalance of the luminal mucosal homeostasis in genetically
susceptible organisms [29] and [44]. Consequently, an altered balance between regulatory
and inflammatory mediators could contribute to an inappropriate and sustained
inflammatory response probably caused by a dysfunction of the microfloral integrity [17]. IBD
encompasses a range of intestinal pathologies, the 2 major clinical entities (ulcerative colitis
(UC) and Crohn's disease (CD)) show overlapping features and a similar symptom profile
which can include; diarrhea, rectal bleeding, abdominal pain and weight loss [34] and [23].
2.1. Crohn's disease (CD)
It is often associated with a widespread inflammation that can affect any region of the
intestine from the mouth to the anal canal but mostly involves the ileum and the colon [59].
At the histological level, CD is characterized by the spread of lymphoid aggregates in the
mucosa and submucosa layers of the bowel. At the beginning of the disease, neutrophil
infiltrates are observed in the epithelial layer. As the disease progresses, neutrophils
infiltrate into the crypts. They form crypt abscesses, hence destroying the crypt leading to
colonic atrophy. Another observed feature resulting from this chronic inflammation is the
formation of non-necrotizing granulomas. Ulcers constitute also a main feature of CD which
enlarge and may then develop into a network of long perforating ulcerations [46]. These
microscopic changes ultimately lead to a series of complications including: abdominal pain,
diarrhea which is a common presentation of CD, rectal bleeding, fistula and perianal
disease which are often very difficult to treat, and malabsorption often due to the
inflammation of the terminal ileum (59).
The profile of cytokines ruling the inflammation of Crohn's disease, while well defined,
continues to be a work in progress. A Th17 response is the main cause of Crohn's disease
inflammation through the production of IL-17 and IFN-γ. These are not, of course, the only
cytokines taking part in the CD inflammation, their downstream cytokines: TNF-α, IL-6 and
IL-1 play pivotal roles as the immediate effectors of inflammation, in addition to several
others including IL-22 [60].
2.2. Ulcerative colitis
UC is also an inflammatory disease featuring recurrent and chronic inflammation of the
colonic mucosa and submucosa [25]. It usually begins in the rectum. Depending on the
severity and the course of the disease; it could extend to the proximal parts in a continuous
fashion [58]. In severe cases, acute dilatation of the colon, necrosis, perforation and
massive hemorrhage with the formation of pseudopolyps are clinically manifested [19].
Histologically, UC can result in crypt abscesses with neutrophils infiltrating the crypts.
Moreover, in severe cases, hypertrophy of the muscularis mucosa can occur which may lead
to a narrowing and shortening of the colon [46].
Typical symptoms of UC include rectal bleeding or bloody diarrhea associated with
abundant mucus discharge, abdominal pain, fever, weight loss and malaise [19]. The
presence of these symptoms and their severity correlate with the activity of the disease [59].
The predominant cytokines in UC are mainly from the Th2 pattern of the adaptive immune
response which produces several pro-inflammatory cytokines such as IL-4, IL-5 and IL-13
[41].
3. Diabetes mellitus
Diabetes mellitus (DM) is a chronic disease that is classified into two major types: type 1
diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T2DM constitutes 90% of all
diabetes and is a common endocrine disorder. On the other hand, T1DM is an
immunologically mediated disorder. It is insulin-dependent diabetes whereby the body's
immune system destroys the βeta cells that release insulin and eventually eliminating insulin
production from the body. However, in T2DM, the body cannot use the insulin leading to
insulin resistance [8].
Insulin resistance and β-cell dysfunction are considered as early and critical components in
the pathophysiology of T2DM. In addition, a timely inflammatory process has been
described with the up regulation of growth factors like TGFβ and pro-inflammatory cytokines
like IL-1β and other biological molecules like ROS [18], [50] and [51].
4. Colorectal cancer
It is well established that CRC originates from the epithelial cells lining the colon or rectum of
the gastrointestinal tract and represents the third most common form of cancer worldwide
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[22]. Recently, CRC incidence has been increasing along with its mortality rates. Multiple
molecular pathways intersect, thus probably promoting its occurrence. However, there is
constantly an inflammatory reaction persisting and maintained. Whereby, an array of pro-
inflammatory mediators is elevated both locally and systemically, such as; cyclooxygenase 2
(COX-2), prostaglandin E2 (PGE2), TNF α, NFkB, TGFβ among others …. Despite the
multiple factors responsible for its onset, its incidence and prevalence increase more in
patients with IBD and/or T2DM [13], [17] and [21].
5. TGFβ
TGF-β constitutes a common factor in all the three disease entities. It is a multifunctional
cytokine that plays an important role in the regulation of many cellular pathways including cell
growth, apoptosis, differentiation and immune reactions. Under normal conditions, TGF-β is
a strong anti-inflammatory cytokine exerting a suppressive effect on carcinogenesis by
inhibiting abnormal cell growth. The uncontrolled cell growth and differentiation in many GI
cancers are attributed to a genetic loss of TGF-β signaling molecules and an alteration of
TGF-β receptors. Once a tumor has developed, TGF-β will promote tumor cell growth,
enhance invasiveness and metastasis and inhibit immune surveillance [51] and [53].
During the pathogenesis of T2DM, TGFβ plays a crucial role in β cell malfunctioning, as
glucotoxicity stimulates TGFβ signaling cascade, moreover, glucotoxicity, which is the
chronic exposure to hyperglycemia, leads to reactive oxygen species (ROS) accumulation
in pancreatic β islets. As anti-oxidative enzymes are not sufficiently present in β cells, ROS
accumulation may result in oxidative stress, a well-known trigger for β cells apoptosis [51]
(Fig. 1). This oxidative stress, along with Free Fatty Acids—FFAs—(secreted by stimulated
adipocytes) abolishes the normal function of β cells and induces the generation of pro-
inflammatory mediators, such as IL-1 β, TNFα and IL-6, thus causing inflammation in
pancreatic islets and peripheral tissues [36]. Consequently, β cell dysfunction may lead to
insulin resistance and disruption of glucose homeostasis. Pro-inflammatory mediators,
such as IL-1 β binds IL-1 receptor (IL-1 R) and leads to NFkB activation, which will interact
with multiple signaling pathways, as will be depicted later on [36] and [51].
Fig. 1. 
The various interactions between TGFβ, Smad 3, IBD, T2DM and colon carcinogenesis are illustrated. Note
that blue arrows indicate induction and stimulation, while red arrow means disruption or inhibition. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article.)
TGFβ and its related factors control the development, growth and function of diverse cell
types. It transmits its signals via dual serine/threonine kinase receptors and transcription
factors called smads, with smad 3 acting as the main facilitator of TGFβ signaling [61].
Several studies illustrate the role of TGFβ/smad3 signaling in the pathogenesis of T2DM. In
a study conducted by Hariom et al. in 2011, smad 3 deficient mice were protected from diet-
induced obesity and diabetes, while systemic blockage of TGFβ signaling protects mice
from diabetes and hepatic steatosis [18]. TGFβ also induces adipocytes hypertrophy and
Figure options
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adipocytes produce FFAs. A prolonged exposure of FFAs to β cells inhibits insulin
synthesis and promotes oxidative stress, leading eventually to insulin resistance [51] (Fig.
1).
Furthermore, the GI tract which is constantly exposed to various pathogens and food
antigens can induce a series of host defensive reactions such as recruitment of immune
cells, activation of anti-inflammatory enzymes and secretion of anti-inflammatory cytokines.
Regulatory T (Treg) cells are among the various regulatory mechanisms whose function is
partly to maintain the gut barrier and other immune reactions in order to prevent a
pathological inflammation and maintain GI tract homeostasis through tolerance. In addition
IL-6, plays an important role in inflammation, a key field of action of IL-6 is the regulation of T
cell differentiation and activation. Numerous studies provided evidence that IL-6 is a critical
regulator of murine models of experimental colitis. It was proven that IL-6 inhibition,
decreases the multiplication and size of colonic adenomas in Azoxymethane (AOM) and
Dextran sodium sulfate (DSS) mice models [52]. The key factor and regulator of IL-6 in
chronic intestinal inflammation works via th1 and th17 cells [14]. IL-6, through its trans-
signaling can also modulate epithelial cells, neutrophils, macrophages and T cells. In
addition, IL-6 promotes the production of th17 cells and TGF-β and induces the maintenance
of IL-17 signaling T lymphocytes in inflamed tissues while it exerts a suppressive effect on
the generation of regulatory T cells (Treg). Moreover, IL-6 is an important factor for the
synthesis of C-reactive protein whose level is found to be elevated in acute and chronic
inflammation. Furthermore, IL-6 plays a potential role in the pathogenesis of diabetes
through mediating local inflammation and tissue destruction in a NOD mouse model. It was
also reported that IL-6R signaling blockage and STAT-3 activation lead to a T cell apoptosis
in lamina propria cells in culture [42]. Fig. 2 demonstrates that TGF β has a role in the
pathogenesis of IBD, and it also may contribute to the cancer risk associated with chronic
inflammation of the gut. TGF β in the presence of IL-6, which is produced during active
infections or other inflammatory states, leads to the differentiation of naïve T cells into Th-17
cells, a set of T helper cells secreting IL-17, a potent inflammatory cytokine. The production
of IL-17 leads to chemokine expression such as IL-6 and TNFα [30]. Th-17 appears to play
an important role in IBD, and drives a pro-carcinogenic process under poorly regulated pro-
inflammatory conditions [49] (Fig. 2).
Fig. 2. 
TGF β creates a cancer-promoting feedback loop and is related through various pathways to IBD, CRC and
T2DM. Note that blue arrows mean induction or stimulation. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)
TGFβ also contributes to epithelial to mesenchymal transition (EMT), a hallmark that
facilitates metastasis and invasion through multiple signaling mechanisms, leading
eventually to tight junctions (TJ) and adherent junctions (AJ) dissolution. Another
mechanism, by which TGFβ facilitates EMT, is through the up regulation of
metalloproteinases (MMPs), contributing to colon carcinogenesis and metastasis [24] (Fig.
2).
In a study conducted by Hawinkels et al. in 2014, a strong activation of TGF-β/Smad
signaling pathway was observed in CRC. TGF-β1 stimulation caused a remarkable up
Figure options
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regulation of MMPs, plasminogen activator inhibitor-1 (PAI-1) and TGF-β1 itself, thus,
leading to cumulative production of TGF-β and proteinases within the tumor
microenvironment and consequently creating a cancer-promoting feedback loop [32] (Fig.
2).
Actually, in IBD a battery of cytokines were described as being secreted (TNFα, IL-6, IL-17,
IL-27 among others), which contribute to the formation of a tumor supporting
microenvironment.
Macrophages, phagocytic cells of the innate immune system, are essential not only for
engulfing foreign agents that enter the body, but also for eliminating apoptotic cells and
digesting wastes from tissues. The activity of macrophages can be increased by cytokines
secreted by helper T cells, especially IFN-γ. During inflammation, macrophages release a
wide range of pro-inflammatory cytokines such as TNF-α, IL-6, IL-8 and IL-12, in addition to
the release of chemokines, prostaglandins and complement. The interactions of all of these
mediators could lead to an increased vascular permeability and recruitment of inflammatory
cytokines [26]. Consequently, environmental triggers like microbiota and inflammation
together can result in damage to the epithelial cells. The increase in inflammatory cells and
the factors they produce result in oxidative stress, which can induce DNA damage resulting
in genetic and epigenetic alterations to the epithelial cells, thus causing dysplasia, cancer
and clonal expansion of these cells. The net result is disruption of the balance of mediators
with increase in TGFβ, IL-6 and TNFα among others leading to IBD, CRC and consequently
T2DM.
Among the different cytokines, IL-13 and IL-4 secreted by Th2 cells have been shown to
increase the colonic mutations in epithelial cells, to support angiogenesis and to produce
TGFβ. In addition, cytokines secreted by Th-17 are proven to be mitogenic. Fig. 3 shows the
different effector cells recruited in IBD and their associated cytokines [16].
Fig. 3. 
The different effector cells recruited in IBD and their associated cytokines leading to a disbalance in pro and
anti-inflammatory agents. Note that blue arrows indicate induction, or stimulation and red color (circle and
arrow) means mitogenic stimulation. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
6. NFKB
There are several lines of evidence posing NFKB as a key regulator in the crosstalk among
the pathways leading to T2DM, CRC, and IBD. Actually, various carcinogens, growth
factors, inflammatory stimuli including microbiota and pro-oxidants activate the transcription
factor NFkB which plays a central role in inflammation and is mostly expressed in cancers
[37]. It was documented that NFkB is activated via phosphorylation of inhibitor of kappa B
(IKB) leading to its ubiquitination and proteasomal degradation. Such a reaction will unmask
the nuclear localization signal of NF-KB, and once in the nucleus, it will activate several
genes that regulate proliferation, apoptosis, angiogenesis, invasion, inflammation and
metastasis [63] and [47] (Fig. 4).
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Fig. 4. 
NFkB the matchmaker between, inflammation, IBD, CRC and T2DM and their wide mechanisms of action.
Note that blue arrows mean induction or stimulation. (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article.)
NFKB plays a major role in linking chronic inflammation to cancer development through its
ability to up regulate several inflammatory, and tumor promoting cytokines such as IL-6, IL-
1α and TNF-α, as well as survival genes such as BCL2 and BCLXL [63] (Fig. 4).
In a study conducted by Greten FR et al. in 2004, a crucial role for IKK beta was
demonstrated, linking inflammation to cancer in a mouse model of colitis-associated
cancer, deleting IKK beta in myeloid cells resulted in a significant decrease in tumor size.
This deletion also diminished the expression of pro-inflammatory cytokines [12] (Fig. 4).
In addition, NFkB promotes EMT, through its activation of snail and twist [5] in the
microenvironment, and the expression of inflammatory cytokines. Moreover, NFKB seems
to be involved in the tumor associated macrophage (TAM) recruitment and acts in cancer-
associated fibroblasts (CAF), by promoting the expression of a pro-inflammatory gene
signature, which is important for macrophage recruitment, neovascularization and tumor
growth that were abolished when NFKB was inhibited [1] and [40] (Fig. 4).
Furthermore, NFKB plays an important role in T2DM, as obesity activates the transcription
factor NFKB which increases the risk for T2DM. It has been shown that NFKB pathway
inhibition exerts a beneficial effect on T2DM, salsalate a prodrug that reduces NFkB activity
was shown to decrease HBA1C levels [38].
Collectively, NFKB could be considered as the matchmaker between inflammation, IBD,
cancer and diabetes, and its wide mechanisms of action are summarized in Fig. 4.
7. TNFα
TNFα is a cytokine produced by activated macrophages as well as other cells. It is one of the
first cytokines to be released during the acute inflammatory response. It plays a pivotal role in
systemic inflammation as it induces the synthesis of C-reactive protein, vasodilatation, and
vascular permeability and helps in the recruitment of inflammatory cells. In harmony with IL-
17, TNF-α triggers the expression of neutrophil-attacking chemokines CXCL1, CXCL2 and
CXCL5 which in turn increase CXCR2-dependent neutrophil migration to the inflammation
site. Diapedisis is also facilitated through TNF-α's effect on cell adhesion molecules
[15] and [54] (Fig. 5).
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Fig. 5. 
TNFα relates to various molecules leading to IBD, CRC, and T2DM.
Among the immune-regulatory factors, TNF α is increased in the mucosa of IBD patients,
and has been shown to play a central role in the pathogenesis of the disease, and anti TNF α
therapy has proven to be beneficial in the treatment of IBD [28]. In addition, TNFα activates
other signaling pathways such as NFkB and Mitogen-activated protein kinases (MAPK)
pathway, resulting in Jun N-terminal kinase (JNK) and the activator protein 1 (AP-1) activity.
Thus the sustained activity of both NFκB and AP-1 is known to be a mediator in distinct
phases of colon carcinogenesis [11] (Fig. 5).
More than a decade ago, it was discovered that TNFα is overexpressed in the adipose
tissues of obese mice, thereby establishing a clear link between obesity, T2DM and chronic
inflammation [64]. Consequently, as represented in Fig. 5, TNF α is a key player in IBD, CRC
and T2DM.
The association between T2DM and cancer is validated in several studies: Orsini and Wolk
demonstrated from a meta-analysis of 15 studies including more than 2.5 million patients
that diabetic people have 30% increased risk of developing CRC compared to non-
diabetics [48]. 371 million people worldwide have DM [56]. Seshasai et al. stated in a review
based on 97 prospective studies that 123,205 cases of mortality of cancer were linked to
diabetes among a total mortality of 820,900 cases. The relative risk of diabetes associated
to CRC is 1.40 with 95% confidence interval (CI) [10] and [56].
On the other hand several studies investigated the correlation between T2DM and IBD in
2015, SY LEE et al. showed that metformin which is an effective widely used T2DM
treatment was able to decrease the severity of IBD and diminishes inflammation [31].
8. The link of microbiota to IBD, T2DM and CRC
The role of dysbiosis in the pathogenesis of IBD, CRC, and T2DM is being strengthened by
several studies and reports involving probiotics. The term “probiotics”, meaning “for life” in
Greek, was first used in 1965 to describe any substance or organism that was beneficial in
promoting microfloral balance in the intestinal system [9]. The Beneficial role of probiotics in
IBD, CRC and T2DM was demonstrated in several studies [3]. XuZ et al. showed that the
probiotic bifidobacterium could significantly ameliorate the disorder of glucose and lipid
metabolism [65]. Furthermore a clinical study investigated the effect of milk fermented with
Lactobacillus helveticus on blood pressure, glycemic control and cardiovascular risk
factors in T2DM using a randomized, double-blinded, prospective, placebo-controlled
study. The change in fasting blood glucose concentration differed significantly between the
two groups with a larger increase in the placebo group [27]. It has been also reported that
consumption of a symbiotic shake resulted in a significant decrease in fasting glycemia in
T2DM patients [2] ( Fig. 6).
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Fig. 6. 
The beneficial effect of probiotics on T2DM, IBD and CRC. Note that blue arrows mean induction while red
arrows indicate the inhibition. (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
In addition to its inhibiting effect on T2DM, existing evidence clearly support an
immunomodulatory role of probiotics in CRC, particularly its ability to modulate intestinal
inflammation, a well-known risk factor for CRC. Other studies along this line showed that the
administration of L.plantarum Lp91 significantly reduced COX-2 and TNFα while up
regulated IL-10 levels in the colon tissues of mice with TNBS-induced colitis [45]. Another
treatment involving the probiotic mixture VSL#3 led again to reduction in COX-2, NFkB,
TNF-α, IL-6 and inducible nitric oxide synthase, while increasing IL-10 and TGFβ expression
in colonic tissue of rats with dextran sulfate sodium-induced colitis [4].
Beneficial effects of probiotic treatment have been observed with the restoration of normal
goblet cells numbers and stimulation of the mucosal immune system in the patients'
intestinal tract to secrete protective immunoglobulins such as secretory IgA, protective
defensins and bacteriocidins in the colonic lumen [39].
On the other hand, increasing evidence suggests that intestinal microbiota play a role in
initiating, maintaining and determining the severity of IBD. Such effect is limited to a
continuous antigenic stimulation causing chronic intestinal injury concurring to the typical
alterations of the gut associated lymphoid tissue associated with IBD [33].
Furthermore, molecular dynamics of dysbiosis encompass modulation of genotoxic
metabolites from different bacterial strains and are able to induce CRC formation in the
presence of polymorphisms responsible of reduced activity of NOD2 [7]. Dysbiosis was
proven to exert detrimental effects on the mechanisms responsible of cellular differentiation,
apoptosis and proliferation control [6]. The great importance of colonic microbiome in CRC
development is substantiated by experiments of stool transfer from individuals with colon
cancer and healthy germ-free mice [55]. They showed that regular probiotics intake may
actively prevent the initiation and development of CRC [17].
The common positive effect of probiotics on T2DM, IBD and CRC may help in clarifying the
pathological link, or links between these 3 chronic diseases. Could it be dysbiosis?
9. Conclusion
Inflammation is a fundamental homeostatic response triggered by both endogenous and
exogenous noxious stimuli. It ensures the integrity of the organisms. However, inflammation
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may be the mysterious cause of several diseases including, neurodegenerative disorders,
atherosclerosis, T2DM, cancer and IBD among others. On the other hand, IBD, CRC and
T2DM are commonly occurring interrelated clinical problems. They share a common basis
influenced by disease-related inflammation, a process characterized by up regulation of
expression of common inflammatory cytokines along with TGFβ, TNFα, NFKB, ROS and
other signaling molecules, leading to an imbalance in the intestinal microbiota. The
intersection between and the converging of all these molecular pathways constitute a
crosstalk leading, most likely to these three interrelated chronic diseases. However, further
clinical studies seem necessary to clarify the complex interplay between CRC, IBD and
T2DM in addition to the role of microbiota in this loop.
A treatment that can interrupt the cross talk could probably be of interest in managing the
three disease entities and form a novel therapeutic target. Would probiotics interrupt the
crosstalk or orient it in the physiological direction?
References
M.Z.D. Ahmed, R. Xu
Nuclear factor-kappaB in inflammatory bowel disease and colorectal cancer. S –
Am. J. Dig. Dis. (2014)
A. Ostadrahimi, A. Taghizadeh, M. Mobasseri, N. Farrin, L. Payahoo, Z.B. Gheshlaghi, M.
Vahedjabbari
Effect of probiotic fermented milk (Kefir) on glycemic control and lipid profile in type 2 diabetic
patients: a randomized double-blind placebo-controlled clinical trial
Iranian J. Public Health (2015)
M. Bellavia, F. Rappa, M. Lo Bello, et al.
Lactobacillus casei and Bifidobacterium lactis supplementation reduces tissue damage of
intestinal mucosa and liver after 2,4,6-trinitrobenzenesulfonic acid treatment in mice
J. Biol. Regul. Homeost. Agents, 28 (2) (2014), pp. 251–261
View Record in Scopus
C. Dai, C.Q. Zheng, F. Meng, Z. Zhou, L. Sang, M. Jiang
VSL#3 Probiotics Exerts the Anti-Inflammatory Activity via PI3k/Akt and NF-κB Pathway in rat
Model of DSS-Induced Colitis—Molecular and Cellular Biochemistry
Springer (2013)
C. Min, S.F. Eddy, D.H. Sherr, G.E. Sonenshein
NF-κB and Epithelial to Mesenchymal Transition of Cancer. Journal of Cellular Biochemistry
Wiley Online Library (2008)
D. Collins, A.M. Hogan, D.C. Winter
Microbial and viral pathogens in colorectal cancer
Lancet Oncol., 12 (5) (2011), pp. 504–512
Article |  PDF (231 K) | View Record in Scopus
A. Couturier-Maillard, T. Secher, A. Rehman, et al.
NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer
J. Clin. Invest., 123 (2) (2013), pp. 700–711
View Record in Scopus
D. Cannata, Y. Fierz, A. Vijayakumar, D. LeRoith
Type 2 Diabetes and Cancer: What is the Connection? Mount Sinai Journal of Medicine
Wiley Online Library (2010)
DM Lilly, RH Stillwell. Probiotics: growth-promoting factors produced by microorganisms—Science,
1965.
D.R. Whiting, L. Guariguata, C. Weil, J. Shaw
IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030—
Diabetes Research and Clinical Practice
Elsevier (2011)
F. Balkwill
Tumour necrosis factor and cancer
Nat. Rev. Cancer, nature (2009)
F.R. Greten, L. Eckmann, T.F. Greten, J.M. Park, Z.W. Li, M.F. Kagnoff, L.J. Egan, et al.
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer.
Cell
Elsevier (2004)
G.A.P. Ganepola, J. Nizin, J.R. Rutledge, D.H. Chang
Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer
J. Gastrointestinal Enterology (2014)
G. Hundorfean, M.F. Neurath, J. Mudter
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 11/27
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
Functional Relevance of T Helper 17 (Th17) Cells and the IL-17 Cytokine Family in
Inflammatory Bowel Disease. Inflammatory Bowel Diseases
Wiley Online Library (2012)
G.K. Griffin, G. Newton, M.L. Tarrio, D. Bu, P. Alcaide, V. Azcutia, E.M. Garcia, et al.
IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects
on endothelial activation
J. Immunol. (2012)
G. Monteleone, F. Pallone, C. Stolfi
The dual role of inflammation in colon carcinogenesis
Int. J. Mol. Sci. (2012)
G. Tomasello, P. Tralongo, P. Damiani, E. Sinagra, B. Trapani, M.N. Zeenny, I.H. Hussein, A. Jurjus,
A. Leone
Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of
colocytes
World J. Gastroenterol. (2014)
H. Yadav, C. Quijano, A.K. Kamaraju, O. Gavrilova, R. Malek, W. Chen, P. Zerfas
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling, Cell Metabolism
Elsevier (2011)
I.A. Hajj Hussein, R. Tohme, K. Barada, M.H. Mostafa, J.N. Freund, R.A. Jurjus, W. Karam, A. Jurjus
Inflammatory bowel disease in rats: bacterial and chemical interaction
World J. Gastroenterol. (2008)
I. Andújar, M.C. Recio, R.M. Giner, E. Jovellanos, S. Laghi, B. Muguerza, J.L. Ríos
Inhibition of ulcerative colitis in mice after oral administration of a polyphenol-enriched cocoa
extract is mediated by the inhibition of STAT1 and STAT3 phosphorylation in colon cells
J. Agric. Food Chem. (2011)
I. Cheng, C.P. Caberto, A.L. Jones, A. Seifried, L.R. Wilkens, F.R. Schumacher, K.R. Monroe
Type 2 diabetes risk variants and colorectal cancer risk: the multiethnic cohort and PAGE
studies
Gut (2011)
I. Crncec, P. Pathria, J. Svinka, R. Eferl
Induction of Colorectal Cancer in Mice and Histomorphometric Evaluation of Tumors, Mouse
Models of Cancer: Methods in Molecular Biology
Springer (2015)
J.J. Kim, S. Shajib, M.M. Manocha, W.I. Khan
Investigating intestinal inflammation in DSS-induced model of IBD
J. Vis. Exp. (2012)
J. Massagué
TGFβ in Cancer, Cell
Elsevier (2008)
J. Meier, ASturm
Current treatment of ulcerative colitis
World J. Gastroenterol. (2011)
J. Rugtveit, E.M. Nilsen, A. Bakka, H. Carlsen, P. Brandtzaeg, H. Scott
Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from
inflammatory bowel disease
Gastroenterology (1997)
KD Hove, C Brøns, K Fae: rch, SS Lund, P Rossing, A Vaag Effects of 12 weeks of treatment with
fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients
with type 2 diabetes: a randomised double-blind placebo-controlled study—Eur. J. Endocrinol., 2015.
K.A. Papadakis, S.R. Targan
Role of cytokines in the pathogenesis of inflammatory bowel disease
Annu. Rev. Med. (2000)
K.J. Maloy, F. Powrie
Intestinal homeostasis and its breakdown in inflammatory bowel disease
Nature (2011)
L.A. Feagins
Role of Transforming Growth Factor-β in Inflammatory Bowel Disease and Colitis-Associated
Colon Cancer—Inflammatory bowel diseases
Wiley Online Library (2010)
Lee, S.H. Lee, E.K. Kim, J.K. Kim, D.Y. Shin, M.L. Cho
Metformin ameliorates inflammatory bowel disease by suppression of STAT3 signaling
pathway and regulation of the Th17/Treg balance (THER3P. 1001)
J. Immunol. (2015)
L Hawinkels, M Paauwe, HW Verspaget, E Wiercinska, JM van der Zon, K van der Ploeg, PJ Koelink,
et al.. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 12/27
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
fibroblasts—Oncogene, 2014.
C.L. Maynard, C.O. Elson, R.D. Hatton, et al.
Reciprocal interactions of the intestinal microbiota and immune system
Nature, 489 (7415) (2012), pp. 231–241
View Record in Scopus | Full Text via CrossRef
M.C. Mattar, D. Lough, M.J. Pishvaian, A. Charabaty
Current management of inflammatory bowel disease and colorectal cancer
Gastrointest. Cancer Res. (2011)
M.G. Laukoetter, P. Nava, A. Nusrat
Role of the intestinal barrier in inflammatory bowel disease
World J. Gastroenterol. (2008)
M.S.H. Akash, K. Rehman, S. Chen
Role of Inflammatory Mechanisms in Pathogenesis of Type 2 Diabetes Mellitus. Journal of
Cellular Biochemistry
Wiley Online Library (2013)
M.S. Hayden, S. Ghosh
Shared Principles in NF-κB Signaling. Cell
Elsevier (2008)
M.R. Rubin, A.B. Goldfine, D.J. McMahon, D.S. Donovan, S. Cremers, E. Dworakowski, E.J.
Schaefer, et al.
Effects of the Anti-Inflammatory Drug Salsalate on Bone Turnover in Type 2 Diabetes Mellitus
—Endocrine
Springer (2015)
Y. Nami, N. Abdullah, B. Haghshenas, et al.
Assessment of probiotic potential and anticancer activity of newly isolated vaginal bacterium
lactobacillus plantarum 5BL
Microbiol. Immunol., 58 (9) (2014), pp. 492–502
View Record in Scopus | Full Text via CrossRef
N. Erez, M. Truitt, P. Olson, D. Hanahan
Cancer-Associated Fibroblasts are Activated in Incipient Neoplasia to Orchestrate Tumor-
Promoting Inflammation in an NF-κB-Dependent Manner, Cancer Cell
Elsevier (2010)
P.J. Basso, M.T.C. Fonseca, G. Bonfá, V.B.F. Alves, H. Sales-Campos, V. Nardini, C.R.B. Cardoso
Association among genetic predisposition, gut microbiota, and host immune response in the
etiopathogenesis of inflammatory bowel disease
Braz. J. Med. Biol. Res. (2014)
R. Atreya, J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, et al.
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in
chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo
Nat. Med. (2010)
R.B. Sartor
Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases
Am. J. Gastroenterol. (1997)
R.J. Xavier, D.K. Podolsky
The pathogenesis of inflammatory bowel disease
Nature (2007)
R.K. Duary, M.A. Bhausaheb, V.K. Batish, S. Grover
Anti-Inflammatory and Immunomodulatory Efficacy of Indigenous Probiotic Lactobacillus
Plantarum Lp91 in Colitis Mouse Model. Molecular Biology Reports
Springer (2012)
R. Thoreson, J.J. Cullen
Pathophysiology of Inflammatory Bowel Disease: An Overview. Surgical Clinics of North
America
Elsevier (2007)
S.C. Gupta, J.H. Kim, S. Prasad, B.B. Aggarwal
Regulation of Survival, Proliferation, Invasion, Angiogenesis, and Metastasis of Tumor Cells
Through Modulation of Inflammatory Pathways by Nutraceuticals. Cancer Metastasis Reviews
Springer (2010)
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 13/27
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61]
SC Larsson, N Orsini, A Wolk. Diabetes mellitus and risk of colorectal cancer: a meta-analysis—J.
Natl. Cancer Inst. 2005.
S.E. Erdman, T. Poutahidis
Roles for inflammation and regulatory T cells in colon cancer
Toxicol. Pathol. (2010)
S.E. Kahn
The Relative Contributions of Insulin Resistance and Beta-Cell Dysfunction to the
Pathophysiology of Type 2 Diabetes, Diabetologia
Springer (2003)
S. Fischbach, G.K. Gittes
The role of TGF-β signaling in β-cell dysfunction and type 2 diabetes: a review
J. Cytol. Histol. (2014)
S. Grivennikov, E. Karin, J. Terzi, D. Mucida, G.Y. Yu, S. Vallabhapurapu, J. Scheller
IL-6 and Stat3 Are Required for Survival of intestinal epithelial cells and development of
Colitis-Associated Cancer Cancer cell
Elsevier (2009)
S. Hong, H.J. Lee, S.J. Kim, K.B. Hahm
Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-
β signaling
World J. Gastroenterol. (2010)
S.M. Vieira, H.P. Lemos, R. Grespan, M.H. Napimoga, D. Dal-Secco, A. Freitas, T.M. Cunha, et al.
A Crucial Role for TNF-α in Mediating Neutrophil Influx Induced by Endogenously Generated
or Exogenous Chemokines, KC/CXCL1 and LIX/CXCL5—British journal of Pharmacology
Wiley Online Library (2009)
I. Sobhani, V. Jarrousse, S. Guilemeau, et al.
Colon cancer patients' microbiome induces intestinal precancerous change in germ-free mice
Gut, 60 (3) (2011), p. A1
S.R. Seshasai, S. Kaptoge, A. Thompson, E.D. Angelantonio, P. Gao, N. Sarwar, P.H. Whincup, et
al.
Diabetes mellitus, fasting glucose, and risk of cause-specific death
N. Engl. J. Med., 364 (2011), pp. 829–841
S.U. Seo, G.Y. Chen, G. Núñez, N. Kamada
Role of the gut microbiota in immunity and inflammatory disease
Nat. Rev. Immunol. (2013)
T. Kühbacher, S. Schreiber, U.R. Fölsch
Ulcerative Colitis: Conservative Management and Long-Term Effects. Langenbeck's Archives
of Surgery
Springer (2004)
V.T. Chandrasekar, N. Venu
So What Is Crohn's disease and Ulcerative Colitis? Pathophysiology of Crohn's disease and
Ulcerative Colitis. Inflammatory Bowel Disease
Springer (2015)
W. Strober, F. Zhang, A. Kitani, I. Fuss, S. Fichtner-Feigl
Pro-inflammatory cytokines underlying the inflammation of Crohn's disease
Curr. Opin. Gastroenterol. (2010)
X.H. Feng, R. Derynck
Specificity and versatility in TGF-β signaling through Smads
Rev. Cell Dev. Biol. (2005)
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 14/27
[62]
[63]
[64]
[65]
X. Wu, V.S. Conlin, V. Morampudi, N.R. Ryz, Y. Nasser, G. Bhinder, K.S. Bergstrom, et al.
Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis and protection
against colitis in mice
PLoS One (2015)
Y. Ben-Neriah, M. Karin
Inflammation Meets Cancer, with NF-[Kappa] B as the Matchmaker—Nature Immunology
(2011)
Z. Liu, R.S. Brooks, E.D. Ciappio, S.J. Kim, J.W. Crott, G. Bennett, A.S. Greenberg, et al.
Diet-Induced Obesity Elevates Colonic TNF-α in Mice and is Accompanied by an Activation of
Wnt Signaling: A Mechanism for Obesity-Associated Colorectal Cancer—The Journal of
Nutritional Biochemistry
Elsevier (2012)
Z. Xu, R. Wang, Y. Yang, R. Dai, J. Shang, Q. Yu
Intervention Effect of Probiotic Bifidobacterium on Type 2 Diabetes Mellitus Rats—Journal of
Hygiene Research
(2014)
Corresponding author at: Department of Anatomy and Regenerative Biology, The George Washington
University School of Medicine and Health Sciences, 461B Ross Hall, 2300 I Street, NW, Washington,
DC 20037, USA.
Copyright © 2015 The Authors. Published by Elsevier B.V.
 
Recom m ended articles
Prophylact ic ef fects of asiat icoside-bas…
Select ive deuterat ion for molecular insi…
Relat ionships between funct ional genes…
View more articles »
2015, Chinese Journal of Natural Medicines more
2015, Chemistry and Physics of Lipids more
2015, Journal of Dairy Science more
 
C i ting articles (0)
 
Related book content
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 15/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 16/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 17/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 18/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 19/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 20/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 21/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 22/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 23/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 24/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 25/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 26/27
15/12/2015 Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links
http://www.sciencedirect.com/science/article/pii/S2214647415000975 27/27
